Immunotherapy for cardiovascular disease

The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outco...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal Vol. 40; no. 48; p. 3937
Main Authors: Lutgens, Esther, Atzler, Dorothee, Döring, Yvonne, Duchene, Johan, Steffens, Sabine, Weber, Christian
Format: Journal Article
Language:English
Published: England 21.12.2019
Subjects:
Cardiovascular disease
Inflammation
Cytokines
Novel targets
Novel therapies
Coronary artery disease
ISSN:1522-9645, 1522-9645
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1522-9645
1522-9645
DOI:10.1093/eurheartj/ehz283